Nadim Ahmed

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Family Promise is a national movement that aims to provide every family with a home, livelihood, and the opportunity to build a better future. The non-profit company is based in Summit, NJ. The organization works in over 200 communities across 43 states to ensure that families experiencing or at risk of homelessness have a safe place to call home. Family Promise delivers innovative solutions for family homelessness, including prevention, shelter, and stabilization services. Family Promise aspires to change the future for 1 million children by 2030 through its community-based programs. The organization was founded more than 30 years ago as a local initiative in Summit, NJ, and has since served over 1 million family members.

GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.

Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Part of Otsuka Holdings Co., Ltd., Cullinan Pearl Corp. is a private company that develops an orally available tyrosine kinase inhibitor. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. Cullinan Pearl was acquired by Taiho Pharmaceutical Co., Ltd. from Cullinan Oncology, Inc. on June 23, 2022 for $405 million.

Part of Cullinan Therapeutics, Inc., Cullinan Mica Corp. is a private company that provides worldwide rights to CLN-619. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed.